Patients with obesity can now get Zepbound’s strongest doses for a flat rate through Lilly’s self-pay pharmacy.

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

Madrigal Pharma's REZDIFFRA sees 33% Q1 2025 sales growth, strong EU progress, and promising MASH data. Read why I maintain ...

Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new ...

Shares in Novo Nordisk fell as much as 3.5 per cent on Monday after detailed trial data on its experimental obesity drug ...

Separately, Novo Nordisk presented early data for its oral amycretin program. In Phase I and Ib/IIa trials, amycretin ...

Baron Funds, an investment management company, released its “Baron Fifth Avenue Growth Fund” first quarter 2025 investor ...

Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, ...

Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...